Cases & Deals

MedImmune licenses in IP on antibodies that target IL-5 receptor

Clients MedImmune, Inc.

Jones Day represented MedImmune in an exclusive license to BioWa's POTELLIGENT technology platform and related intellectual property directed to antibodies that target the interleukin-5 (IL-5) receptor, including the transfer of Phase I clinical trials for treatment of asthma and other inflammatory diseases.